Graham Capital Management L.P. acquired a new stake in Enhabit, Inc. (NYSE:EHAB - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 76,918 shares of the company's stock, valued at approximately $601,000. Graham Capital Management L.P. owned approximately 0.15% of Enhabit as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in EHAB. JPMorgan Chase & Co. increased its stake in shares of Enhabit by 37.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 305,245 shares of the company's stock worth $2,411,000 after acquiring an additional 83,707 shares during the last quarter. Empowered Funds LLC increased its position in Enhabit by 5.0% during the fourth quarter. Empowered Funds LLC now owns 175,824 shares of the company's stock worth $1,373,000 after purchasing an additional 8,448 shares during the last quarter. Stoneridge Investment Partners LLC raised its stake in Enhabit by 22.6% during the fourth quarter. Stoneridge Investment Partners LLC now owns 12,533 shares of the company's stock worth $98,000 after purchasing an additional 2,308 shares during the period. Rhumbline Advisers raised its position in shares of Enhabit by 2.8% during the 4th quarter. Rhumbline Advisers now owns 80,760 shares of the company's stock valued at $631,000 after buying an additional 2,211 shares during the period. Finally, Paradice Investment Management LLC lifted its holdings in Enhabit by 12.8% in the fourth quarter. Paradice Investment Management LLC now owns 1,780,113 shares of the company's stock valued at $13,903,000 after acquiring an additional 201,997 shares during the last quarter.
Enhabit Trading Up 0.4%
Enhabit stock traded up $0.04 during trading on Tuesday, hitting $10.69. The company had a trading volume of 59,119 shares, compared to its average volume of 335,543. The company's 50 day simple moving average is $8.58 and its 200-day simple moving average is $8.24. Enhabit, Inc. has a 1-year low of $6.85 and a 1-year high of $10.79. The company has a current ratio of 1.46, a quick ratio of 1.46 and a debt-to-equity ratio of 0.85. The stock has a market cap of $541.31 million, a price-to-earnings ratio of -4.61 and a beta of 1.61.
Enhabit (NYSE:EHAB - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.07 by $0.03. The company had revenue of $259.90 million for the quarter, compared to analyst estimates of $266.11 million. Enhabit had a negative net margin of 11.24% and a positive return on equity of 1.67%. As a group, analysts expect that Enhabit, Inc. will post 0.22 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group restated a "buy" rating on shares of Enhabit in a research report on Thursday, March 6th.
Read Our Latest Stock Report on Enhabit
About Enhabit
(
Free Report)
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
Featured Stories

Before you consider Enhabit, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enhabit wasn't on the list.
While Enhabit currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.